Please assess the completion status of the following clinical trial:

Trial Title: Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Any solid tumor that failed standard therapy.~* Patient must have evidence for tumor by CT, MRI, PET scan, MIBG scan, serum markers, or tissue sampling.~* Age ≤ 21 years.~* Karnofsky/Lansky performance status ≥ 50% (Karnofsky score for age\> 16 years and Lansky score for age ≤ 16 years)~* ANC≥ 1000 at least 24 hours off GCSF~* Platelets ≥ 75k at least one week off platelet transfusions~* Hg≥ 8g/dL at least one week off PRBC transfusion~* AST ≤ 3 x the upper limit of normal~* ALT ≤ 3 x the upper limit of normal~* Total bilirubin ≤ 2.0 mg/dl~* serum creatinine ≤ 1.5 x the upper limit of normal for age, or calculated creatinine clearance or nuclear GFR ≥ 70 ml/min/1.73 m2.~* ≥ 3 weeks since last non-nitrosourea chemotherapy~* ≥ 6 weeks since last nitrosoureas~* ≥ 4 weeks since last RT~* Patients must agree to practice adequate contraception. Females of childbearing potential must have a negative B-HCG pregnancy test documented within 14 days prior to drug initiation. Females must not be breast feeding.~* Patients must be able to swallow tablets whole~Exclusion Criteria:~* Pregnancy~* Patients must not have active infection or serious intercurrent medical illness.~* HIV-Positive patients receiving combination anti-retroviral therapy are excluded from the study due to possible retro-viral drug interactions. HIV testing not required.~* Patients must not be taking EIAEDs. If patients were previously EIAEDs that have been discontinued, patients must have been off the agent for at least 2 weeks prior to registration.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- perifosine (Type: EXPERIMENTAL): This will be a dose escalation study to determine the maximum tolerated dose (MTD) of perifosine alone in recurrent/progressive pediatric tumors. A standard 3+3 dose escalation design will be employed with 3-6 patients at each dose level.

Based on this trial design, predict the completion outcome and termination type (if applicable).